An observational study in Optic Neuritis, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by University Hospital, Lille · Observational
This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.
Neurologists and Neuro-Ophthalmologists are in need for reliable and robust imaging biomarkers enabling to predict retinal axonal loss and visual disability after clinical episode of optic neuritis (ON). Length of optic nerve lesion measured on MRI may be one of them.
The aim of our study is to measure the association between the extent of inflammatory demyelinating process on optic nerve at the acute of ON and the retinal degenerative process following optic nerve injury.
The investigators planned to include 50 patients suffering from a recent clinical episode of ON.
Extent of demyelinating inflammatory process will be assessed by the length of optic nerve double inversion recovery (DIR) hypersignal at the acute phase of ON.
The axonal degenerative process following optic nerve demyelinating injury will be assessed by retinal atrophy measured on optical coherence tomography at 12 months after ON, by visual disability measured on low vision contrast acuity scale and by microstructural quality analysis of optic nerve measured on diffusion tensor imaging sequence of the optic nerve.
88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.
This study's enrollment of 46 is below the median of 150 across 25 observational studies indexed under Optic Neuritis.
Browse Optic Neuritis studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients suffering from a recent clinical episode of ON suggestive of demyelinating disease as clinically isolated syndrome, multiple sclerosis or neuromyelitis optica spectrum disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severity of retinal axonal loss around papilla after a clinical episode of optic neuritis
peripapillary RNFL thickness decrease
Time frame: 12 months
Severity of retinal axonal loss within macula after a clinical episode of optic neuritis
macular volume decrease
Time frame: 12 months
Severity of visual disability after a clinical episode of optic neuritis
monocular low contrast (2.5%) vision
Time frame: 12 months
Severity of microstructural architecture of optic nerve after a clinical episode of optic neuritis
fractional anisotropy
Time frame: 12 months
Progression of optic nerve lesion length
lesion length in mm measured on 3D-double inversion recovery sequence
Time frame: 12 months
Plan to share: No
Ran from Feb 2016 to primary completion in Mar 2020, 49 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.